Lower-Dose vs High-Dose Oral Estradiol Therapy of Hormone Receptor–Positive, Aromatase Inhibitor–Resistant Advanced Breast Cancer

JAMA ◽

10.1001/jama.2009.1204 ◽

2009 ◽

Vol 302 (7) ◽

pp. 774 ◽

Author(s):

Matthew J. Ellis ◽

Feng Gao ◽

Farrokh Dehdashti ◽

Donna B. Jeffe ◽

P. Kelly Marcom ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Aromatase Inhibitor ◽

Hormone Receptor ◽

Advanced Breast ◽

High Dose ◽

Hormone Receptor Positive ◽

Download Full-text

0185 High-dose fulvestrant (500 mg): Clinical evidence supporting potentially improved efficacy benefits in hormone receptor-positive (HR+) advanced breast cancer (ABC)

10.1016/s0960-9776(09)70208-5 ◽

2009 ◽

Vol 18 ◽

pp. S65

Author(s):

N. Harbeck ◽

I. Kuter ◽

D. Amakye ◽

J.F.R. Robertson ◽

M.J. Ellis

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Hormone Receptor ◽

Clinical Evidence ◽

Advanced Breast ◽

High Dose ◽

Hormone Receptor Positive

Download Full-text

Abstract GS2-05: First-line ribociclib vs placebo with goserelin and tamoxifen or a non-steroidal aromatase inhibitor in premenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer: Results from the randomized phase III MONALEESA-7 trial

10.1158/1538-7445.sabcs17-gs2-05 ◽

2018 ◽

Author(s):

D Tripathy ◽

J Sohn ◽

S-A Im ◽

M Colleoni ◽

F Franke ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Aromatase Inhibitor ◽

Hormone Receptor ◽

Premenopausal Women ◽

Advanced Breast ◽

Phase Iii ◽

Hormone Receptor Positive

Download Full-text

Tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) with ribociclib (RIB) in premenopausal patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC): MONALEESA-7 subgroup analysis

Annals of Oncology ◽

10.1093/annonc/mdy272.320 ◽

2018 ◽

Vol 29 ◽

pp. viii106-viii107

Author(s):

A. Bardia ◽

S. Campos-Gomez ◽

S.A. Hurvitz ◽

Y.-S. Lu ◽

S.-A. Im ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Aromatase Inhibitor ◽

Subgroup Analysis ◽

Hormone Receptor ◽

Advanced Breast ◽

Hormone Receptor Positive ◽

Premenopausal Patients

Download Full-text

5080 Safety and tolerability of fulvestrant high-dose (500 mg) in postmenopausal women with hormone receptor positive advanced breast cancer

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(09)70972-3 ◽

2009 ◽

Vol 7 (2) ◽

pp. 284-285 ◽

Author(s):

N. Gottschalk ◽

I. Kuter ◽

J.F. Robertson ◽

M.J. Ellis ◽

J. Lindeman ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Postmenopausal Women ◽

Hormone Receptor ◽

Advanced Breast ◽

High Dose ◽

Hormone Receptor Positive

Download Full-text

Ribociclib (RIB) + tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) in premenopausal patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC): MONALEESA-7 patient-reported outcomes (PROs)

Annals of Oncology ◽

10.1093/annonc/mdy272.283 ◽

2018 ◽

Vol 29 ◽

pp. viii91

Author(s):

N. Harbeck ◽

R. Villanueva ◽

F. Franke ◽

G. Babu ◽

P. Wheatley-Price ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Aromatase Inhibitor ◽

Hormone Receptor ◽

Patient Reported Outcomes ◽

Advanced Breast ◽

Hormone Receptor Positive ◽

Patient Reported ◽

Premenopausal Patients

Download Full-text

Abstract P6-18-04: Ribociclib with a non-steroidal aromatase inhibitor and goserelin in premenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer: MONALEESA-7 age subgroup analysis

10.1158/1538-7445.sabcs18-p6-18-04 ◽

2019 ◽

Author(s):

D Tripathy ◽

S Campos-Gomez ◽

Y-S Lu ◽

F Franke ◽

A Bardia ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Aromatase Inhibitor ◽

Subgroup Analysis ◽

Hormone Receptor ◽

Premenopausal Women ◽

Advanced Breast ◽

Hormone Receptor Positive

Download Full-text

Ribociclib (RIB) + tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) in premenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) who received prior chemotherapy (CT): MONALEESA-7 subgroup analysis.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.1047 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. 1047-1047

Author(s):

Sara A. Hurvitz ◽

Paul Wheatley-Price ◽

Debu Tripathy ◽

Yen-Shen Lu ◽

Louis Chow ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Aromatase Inhibitor ◽

Subgroup Analysis ◽

Hormone Receptor ◽

Premenopausal Women ◽

Advanced Breast ◽

Prior Chemotherapy ◽

Hormone Receptor Positive

Download Full-text

Ribociclib (RIB) + non-steroidal aromatase inhibitor (NSAI) + goserelin in premenopausal Asian women with hormone-receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC): Results from the randomized phase III MONALEESA-7 study

Annals of Oncology ◽

10.1093/annonc/mdy428 ◽

2018 ◽

Vol 29 ◽

pp. ix13 ◽

Author(s):

S.-A. Im ◽

J. Sohn ◽

D. Tripathy ◽

L. Chow ◽

K.S. Lee ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Aromatase Inhibitor ◽

Hormone Receptor ◽

Advanced Breast ◽

Phase Iii ◽

Asian Women ◽

Hormone Receptor Positive

Download Full-text

Abstract P1-19-09: Updated subgroup tumor response of abemaciclib plus aromatase inhibitor for hormone receptor positive (HR+), HER2 negative advanced breast cancer (MONARCH 3)

10.1158/1538-7445.sabcs19-p1-19-09 ◽

2020 ◽

Author(s):

Joyce O’Shaughnessy ◽

Stephen Johnston ◽

Miguel Martin ◽

Jens Huober ◽

Masakazu Toi ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Aromatase Inhibitor ◽

Hormone Receptor ◽

Tumor Response ◽

Advanced Breast ◽

Hormone Receptor Positive

Download Full-text

Ribociclib + letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative advanced breast cancer (ABC) who received no prior therapy for advanced disease

Geburtshilfe und Frauenheilkunde ◽

10.1055/s-0036-1592812 ◽

2016 ◽

Vol 76 (10) ◽

Author(s):

EM Grischke ◽

A Nusch ◽

N Marschner ◽

W Abenhardt ◽

J Wilke ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Postmenopausal Women ◽

Hormone Receptor ◽

Advanced Disease ◽

Advanced Breast ◽

Prior Therapy ◽

Hormone Receptor Positive

Download Full-text